MR1 and central nervous system cancer: For MR1 high- versus low-expressing gliomas, grade II had 66 versus 180 samples with 23 485 genes differentially expressed; grade III had 64 versus 196 samples with 24 053 genes differentially expressed; and grade IV had 90 versus 61 samples with 22 962 genes differentially expressed (Figure 4A).